Join to access to all OVN content. Join for Free
Field Medical Execution Despite Limited Resources
Neurology MSLs managing MSL teams virtual platforms impact engaging KOLs strategies future of MSL role

Field Medical Execution Despite Limited Resources


Share This Article


Summary

In this episode, Ed Cunningham delves into his extensive background in Neurology MSLs and shares insights on managing MSL teams, including the role of outsourcing. He explores the impact of virtual platforms and technology on MSL interactions, and offers strategies for engaging KOLs in the post-COVID landscape. Ed addresses the challenges of maintaining effectiveness in large territories, and discusses metrics for performance measurement in Medical Affairs. The conversation extends to the future of the MSL role, hybrid work models, and the evolving value of MSLs to stakeholders. The episode concludes with closing remarks and sponsorship from Synovian Pharmaceuticals.

My guest today is Ed Cunningham, Executive Director, Neurology MSLs with Sunovian Pharmaceuticals shares insights for Field Medical Execution Despite Limited Resources

Ed discusses…

👉 How to lead MSL teams with limited resources
👉 The importance of outsourcing to support field-based efforts and activities
👉 Virtual and alternative platforms to share data and gather insights
👉 What are best practices for prioritizing KOL engagement and tracking
👉 How budget plays a factor
👉 How an MSL can maintain effectiveness in a very large territory
👉 How an MSL can adapt a territory plan to accomplish objectives

Click for Source
Neurology MSLs, managing MSL teams, virtual platforms impact, engaging KOLs strategies, future of MSL role

Related Topics

Meet Our Innovation Partners

Loading partners...

You May Also Like

Article
Methodological and reporting standards for quality-of-life data eligible for European Society for Medical Oncology-Magnitude of Clinical Benefit Scale
OVN Avatar S.F. Oosting, J. Barriuso, A. Bottomley, M. Galotti, B. Gyawali, B. Kiesewetter, N.J. Latino, F. Martinelli, M. Pe, G. Pentheroudakis, F. Roitberg, H. Vachon, E.G.E. de Vries, M. Piccart, N.I. Cherny

Methodological and reporting standards for quality-of-life data eligible for European Society for Medical Oncology-Magnitude of Clinical Benefit Scale

Article
Sponsorship of oncology clinical trials in the United States according to age of eligibility
OVN Avatar Dylan V Neel, David S Shulman, Clement Ma, Florence Bourgeois, Steven G DuBois

Sponsorship of oncology clinical trials in the United States according to age of eligibility

Article
Model-Informed Therapeutic Dose Optimization Strategies for Antibody-Drug Conjugates in Oncology: What Can We Learn From US Food and Drug Administration-Approved Antibody-Drug Conjugates?
OVN Avatar Michael Z. Liao, Dan Lu, Matts Kågedal, Dale Miles, Divya Samineni, Stephanie N. Liu, Chunze Li

Model-Informed Therapeutic Dose Optimization Strategies for Antibody-Drug Conjugates in Oncology: What Can We Learn From US Food and Drug Administration-Approved Antibody-Drug Conjugates?

Article
Finding the Right Drug at the Right Dose the First Time: Has the Era of Personalized Formularies Finally Arrived?
OVN Avatar Karen Geary

Finding the Right Drug at the Right Dose the First Time: Has the Era of Personalized Formularies Finally Arrived?

Article
Liquid biopsy in oncology: a consensus statement of the Spanish Society of Pathology and the Spanish Society of Medical Oncology
OVN Avatar J. Remon, R. García-Campelo, E. de Álava, R. Vera, J. L. Rodríguez-Peralto, Á. Rodríguez-Lescure, B. Bellosillo, P. Garrido, F. Rojo & R. Álvarez-Alegret

Liquid biopsy in oncology: a consensus statement of the Spanish Society of Pathology and the Spanish Society of Medical Oncology

Article
Past, Current, and Future Cancer Clinical Research Collaborations: The Case of the European Organisation for Research and Treatment of Cancer
OVN Avatar Stefanie Broes, Robbe Saesen, Denis Lacombe, Isabelle Huys

Past, Current, and Future Cancer Clinical Research Collaborations: The Case of the European Organisation for Research and Treatment of Cancer

Explore OVN